DMAC — DiaMedica Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $340.54m
- $289.22m
Annual cashflow statement for DiaMedica Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.6 | -13.7 | -19.4 | -24.4 | -32.8 |
| Depreciation | |||||
| Non-Cash Items | 1.78 | 1.55 | 0.53 | 0.817 | 2.99 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.461 | 0.585 | 0.093 | 1.51 | 0.675 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -12.3 | -11.5 | -18.7 | -22.1 | -29.1 |
| Capital Expenditures | -0.022 | -0.081 | -0.024 | -0.025 | -0.04 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -20.5 | 11.6 | -18.3 | 8.59 | -2.15 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -20.5 | 11.5 | -18.3 | 8.56 | -2.19 |
| Financing Cash Flow Items | — | — | — | — | -0.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 30.1 | -0.006 | 36.8 | 12 | 43.9 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.7 | 0.021 | -0.185 | -1.52 | 12.6 |